Invuity (NSDQ:IVTY) said it closed its initial public offering, raising approximately $47.8 million by offering 4.6 million shares at $12 per share. Leerink Partners, Piper Jaffray and Stifel were book-runners for the offering, with William Blair acting as co-manager, the company said. The IPO’s underwriters exercised a 600,000-share over-allotment, the San Francisco, Calif.-based surgical illumination device company […]
UPDATE: Invuity prices IPO at $12 per share, under the range
Invuity yesterday priced its initial public offering at $12 a share, under the range the advanced surgical lighting maker set earlier in June, looking to raise $48 million. Invuity shares were set to begin trading today under the “IVTY” symbol on the NASDAQ exchange, the company said, but plans for opening have been delayed until […]
InVivo hits the NASDAQ exchange
InVivo Therapeutics readies reverse split ahead of NASDAQ listing
Intuitive Surgical cleared by FDA for single-site da Vinci Sp robotic surgery system | Medtech regulatory news for the week of Apr. 28, 2014
Ulthera registers for $86M IPO
Ulthera filed for a U.S. initial public offering yesterday, saying it hopes to raise as much as $86 million when it debuts on the NASDAQ stock exchange.
Mesa, Ariz.-based Ulthera makes an ultrasound device, which is designed to use the body’s natural healing process to non-invasively lift and tighten loose skin on the neck and under the chin.
Vital Therapies prices $54M IPO
Vital Therapies priced its initial public offering at $12 per share, once again lowering the bar for its 1st public flotation after scuttling its 1st try at a U.S. IPO.
Vital Therapies, which is developing a bio-artificial liver, last October set the IPO’s price range at $16-$18. But the San Diego-based company but shelved the offering until March, when it set the range at $13-$15 per share.
Stryker hits a new lifetime high in shares | Medtech Wall Street news for the week of Apr. 7, 2014
Vital Therapies lowers the bar with 2nd IPO try
Bio-artificial liver maker Vital Therapies set the range for its initial public offering at $13 to $15 per share, below the $16 to $18 range it set last year before scuttling its 1st try at a U.S. IPO.
In March Vital Therapies filed updated registration statements signaling its intent to launch the IPO, wiping clean the pricing set in November 2013. Another filing today set the new price range for the 4.5-million-share offering at $58.5 million to $67.5 million.
Lombard Medical sets range for $55m – $65M IPO
Lombard Medical Technologies (LON:LMT) today set the range for its forthcoming U.S. initial public offering, saying it plans to price its shares between $15 apiece and $18.
Lumenis undercuts IPO price at $12 per share, shares gain nearly 9%
Lumenis Ltd. today priced its initial public offering at $12 per share, 20% under the low end of the prior $15-$17 range set by the Israeli maker of medical lasers.
Lumenis shares, trading under the "LMNS" symbol on the NASDAQ exchange, opened up 4.2% at $12.50 today and were fetching $13.05 apiece as of about 11:20 a.m., up 8.8%.
MassDevice Network
@MassDevice
LinkedIn
YouTube